In their pilot study, local low-dose CpG administration, irrespective of GM-CSF co-administration, resulted in increased frequencies of melanoma-specific CD8(+) T cells and possible recruitment of effector NK cells, potentially re-activating an antitumor activity at the SLNs. The gene discussed is CD8A; the disease is melanoma.